EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes

Yuta Suzuki, Hidehiro Kaneko iD, Akira Okada, Jin Komuro, Toshiyuki Ko, Katsuhito Fujiu, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Masaki Ieda, Koichi Node iD, Hideo Yasunaga und 2 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfae158 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Yuta Suzuki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan, Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While the kidney-protective effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors have attracted much attention, there are limited real-world clinical data examining the effects of SGLT2 inhibitors on kidney function in older individuals. We aimed to compare the kidney outcomes between SGLT2 inhibitor and dipeptidyl peptidase 4 (DPP4) inhibitor use in older adults with diabetes.

Methods

Using a nationwide claims database, we studied 6354 older adults (≥60 years of age) who had diabetes and were newly initiated on SGLT2 inhibitors or DPP4 inhibitors. A 1:4 propensity score matching algorithm was used to compare changes in estimated glomerular filtration rate (eGFR) between SGLT2 inhibitor and DPP4 inhibitor users. The primary outcome was a decrease in the rate of eGFR, which was obtained using a linear mixed-effects model with an unstructured covariance.

Results

Following propensity score matching, 6354 individuals including 1271 SGLT2 inhibitor users and 5083 DPP4 inhibitor users {median age 68 years [interquartile range (IQR) 65–70], male 60.4%, median eGFR 69.0 ml/min/1.73 m2 [IQR 59.1–79.0], median haemoglobin A1c [HbA1c] 6.9% [IQR 6.5–7.4]} were analysed. SGLT2 inhibitor users had a slower eGFR decline than did DPP4 inhibitor users [−0.97 ml/min/1.73 m2/year (95% CI −1.24 to −0.70) versus −1.83 ml/min/1.73 m2/year (95% CI −1.97 to −1.69); P for interaction <.001]. This finding remained consistent across subgroups based on age, sex, body mass index, HbA1c level, renin–angiotensin system inhibitor use and baseline eGFR. Additionally, the risk of a ≥20%, ≥30% and ≥40% decrease in eGFR from baseline was significantly lower in SGLT2 inhibitor users than in DPP4 inhibitor users.

Conclusions

Our analysis, utilizing a nationwide epidemiological dataset, demonstrated that the decrease in eGFR was slower in individuals ≥60 years of age with diabetes who were prescribed SGLT2 inhibitors compared with those prescribed DPP4 inhibitors, suggesting a potential advantage of SGLT2 inhibitors for kidney outcomes even in older individuals with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2HumansMaleAgedFemaleGlomerular Filtration RateMiddle AgedFollow-Up StudiesPrognosisRetrospective StudiesGlycated HemoglobinPropensity Score

Stichwörter der Autor:innen

SGLT2 inhibitorschronic kidney diseasediabetesepidemiology

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
  • Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
  • Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

ORCID-Profile: Hidehiro Kaneko, Koichi Node

Förderung

  • Ministry of Health, Labour and Welfare, Japan
  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Suzuki, Y., Kaneko, H., Okada, A., Komuro, J., Ko, T., Fujiu, K., Takeda, N., Morita, H., Nishiyama, A., Ieda, M., Node, K., Yasunaga, H., Nangaku, M., & Komuro, I. (2025). Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae158

Vancouver

Suzuki Y, Kaneko H, Okada A, Komuro J, Ko T, Fujiu K, et al. Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae158

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Yuta and Kaneko, Hidehiro and Okada, Akira and Komuro, Jin and Ko, Toshiyuki and Fujiu, Katsuhito and Takeda, Norifumi and Morita, Hiroyuki and Nishiyama, Akira and Ieda, Masaki and Node, Koichi and Yasunaga, Hideo and Nangaku, Masaomi and Komuro, Issei},
  title = {Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfae158}
}
Kostenlos starten →